Hrubá marže společnosti Financière de Tubize SA
Jaká je hodnota metriky Hrubá marže společnosti Financière de Tubize SA?
Hodnota metriky Hrubá marže společnosti Financière de Tubize SA je -22,250.00%
Jaká je definice metriky Hrubá marže?
Hrubá marže (Gross margin) je rozdíl mezi příjmy a náklady na prodané zboží dělený příjmy a vyjádřený v procentech.
Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.
Hrubá marže společností v sektoru Health Care sektor na EURONEXT ve srovnání se společností Financière de Tubize SA
Čemu se věnuje společnost Financière de Tubize SA?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Firmy s metrikou hrubá marže podobnou společnosti Financière de Tubize SA
- Hodnota metriky Hrubá marže společnosti Magnis Resources je -45,793.10%
- Hodnota metriky Hrubá marže společnosti Pure Minerals je -44,700.00%
- Hodnota metriky Hrubá marže společnosti Condor Technologies NV je -41,600.00%
- Hodnota metriky Hrubá marže společnosti CytoDyn je -27,547.74%
- Hodnota metriky Hrubá marže společnosti Aqua Metals Inc je -25,028.00%
- Hodnota metriky Hrubá marže společnosti Alpha HPA je -22,812.50%
- Hodnota metriky Hrubá marže společnosti Financière de Tubize SA je -22,250.00%
- Hodnota metriky Hrubá marže společnosti Hannans je -20,600.00%
- Hodnota metriky Hrubá marže společnosti Neovacs S.A je -20,146.52%
- Hodnota metriky Hrubá marže společnosti LQwD FinTech je -20,000.00%
- Hodnota metriky Hrubá marže společnosti Interlapse Technologies je -20,000.00%
- Hodnota metriky Hrubá marže společnosti GOLO Mobile je -19,675.47%
- Hodnota metriky Hrubá marže společnosti Coastal Greenland je -18,994.50%